



A program licensed by the
American Society of Clinical Oncology

Annual '09
Meeting

**Slovenská onkologická spoločnosť Vás pozýva na akreditované podujatie
Americkéj spoločnosti klinickej onkológie**

*Slovak Oncology Society invites you to attend the licensed conference of
American Society of Clinical Oncology*

Best of ASCO® Slovakia

3. október 2009/3rd October 2009

Holiday Inn, Bratislava

**Výber toho najlepšieho z kongresu ASCO
prezentované lídrami slovenskej i svetovej onkológie**

*The cutting edge results from ASCO Annual meeting
presented by the leaders of Slovak and world oncology*



PRIHLÁŠKA

Best of ASCO® Slovakia / 3. október 2009/3rd October 2009, Holiday Inn, Bratislava

Meno, priezvisko, titul / *First name, surname, title:* _____

Adresa pracoviska / *Work address:* _____

Tel: _____ Fax: _____ E-mail: _____

Reg. č. Slovenskej lekárskej komory / *No. of Slovak Medical Chamber:* _____

Ubytovanie / *Accommodation:*

z 2. 10. na 3. 10. 2009 / *from October 2nd to October 3rd 2009:* **áno** / *Yes* **nie** / *No*

z 3. 10. na 4. 10. 2009 / *from October 3rd to October 4th 2009:* **áno** / *Yes* **nie** / *No*

Pri prihlásení do 31. 8. 2009 ubytovanie zabezpečí organizátor. / *The organizer will provide the accommodation if applied no later than 31st of August 2009.*

Pri prihlásení po 31. 8. 2009 je potrebné uhradiť registračný poplatok 30,- EUR. / *If registered after 31st of August, the registration fee of 30,- EUR applies.*

V prípade záujmu o účasť vyplnenú prihlášku zašlite poštou, faxom, e-mailom na adresu
Completed applications of attendance may be sent by mail, fax or e-mail to the following address:

POKO Poprad, s. r. o., Mnoholetova 2, 058 01 Poprad

fax: + 421 (0) 52 7763 137, e-mail: pokopopradstro@mail.t-com.sk najneskôr do 31. 8. 2009 / *no later than 31st of August 2009.*

1st Announcement Programme “Best of ASCO® in Slovakia”

Official languages: *Slovak, English*

07.30 – 08.30 *Registration*

08.30 – 08.45 *Welcome*

Chairmen of the breast cancer session – Ivan Koza, Igor Andrašina (08.45 – 10.15)

08.45 – 09.15

1. Adjuvant and neoadjuvant breast cancer (Igor Andrašina)

1. Thjan-Heijnen, V. Impact of omission of completion axillary lymph node dissection (aLND) or axillary radiotherapy (axRT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0(i+)) in the sentinel lymph node (SN): results from the MIRROR study.
2. Watanabe, T. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node positive breast cancer – Results of N-SAS-BC02 trial.
3. Gonzales-Angulo, A. Adjuvant radiation therapy benefits breast cancer patients with 1 to 3 positive lymph nodes undergoing a modified radical mastectomy and systemic therapy.
4. Esserman, L. Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY trial (CALGB 150007/150012, ACRIN 6657).

09.15 – 09.45

2. Metastatic breast cancer (Tanja Čufer)

1. Seidman, A. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC).
2. Robert, N. RIBBON-1: Randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for 1st line treatment of HER2-negative locally-recurrent or metastatic breast cancer (MBC).
3. Vogel, C. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results.
4. O'Shaugnessy, J. Efficacy of BSI-201, a Poly (ADP-ribose) Polymerase-1 (PARP1) inhibitor, in Combination With Gemcitabine/Carboplatin (G/C) in Patients with Metastatic Triple Negative Breast Cancer (TNBC): Results of a Randomized Phase 2 Trial.
5. Tutt, A. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.

09.45 – 10.15

Discussion

Chairmen of the lung cancer session – Peter Kasan, Peter Beržinec (10.15 – 11.00)

10.15 – 10.45

3. Lung cancer (Thomas Brodowicz)

1. Felip, E. Surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage-non-small cell lung cancer (NSCLC): Results of NATCH multicenter, randomized, phase III trial.
2. Fouret, P. MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer.
3. Chlebowski, R. Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the women's health initiative randomized clinical trial.
4. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with 1st line platinum-based chemotherapy in patients with advanced NSCLC.
5. Miller, V. A randomized, double blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of

chemotherapy with B for 1st line treatment of locally-advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).

6. Belani, C. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).

7. O'Byrne, K. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study.

10.45 – 11.15

Discussion

Chairmen of the hematologic malignancies session – Andrej Vranovský, Jan Hudeček, (11.15 – 12.15)

11.15 – 11.45

6. Hematologic malignancies– lymphoma, leukemia (Stanislav Špánik)

1. Schuster, S. Idiotype vaccine therapy (BiovaxIDTM) in follicular lymphoma in first complete remission: phase III clinical trial results.

2. Cunningham, D. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.

3. Gisselbrecht, C. R-ICE versus D-HAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.

4. Fernandez, H. A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.

5. Palumbo, A. A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients.

11.45 – 12.15

Discussion

12.15 – 13.30

Lunch

Chairmen of the urogenital and gynecologic cancer – Tibor Packáň, Jozef Mardiak (13.30 – 15.00)

13.30 – 14.00

7. Urogenital malignancies (Jozef Mardiak)

1. Rini, B. Bevacizumab plus interferon-alpha versus interferon-alpha Monotherapy in Patients wit Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206.

2. Escudier, B. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon- α 2a (IFN) in metastatic renal cell carcinoma (mRCC).

3. Sternberg C. A randomized, double-blind phase III study of Pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).

4. Scher, H. Antitumor activity of MDV3100 in a Phase 1-2 study of Castration-Resistant Prostate Cancer (CRPC).

14.00 – 14.30

8. Gynecologic malignancies (Jan B. Vermorken)

1. Pignata, S. Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): final results of the MITO-2 randomized multicenter trial.

2. Pujade-Lauraine, E. CALYPSO phase III study: comparison of carboplatin (C) pegylated liposomal doxorubicin (PLD) (C-D) and carboplatin-paclitaxel (C-P) in relapsed platinum-sensitive ovarian cancer (OC) by the Gynecologic Cancer Intergroup (GCIG).

3. Herrstedt, J. A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients.

4. Rustin, G. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

14.30 – 15.00

Discussion

Chairmen of the gastrointestinal cancer and varia session – Pavol Dubinský, Vladimír Malec (15.00 – 17.00)

15.00 – 15.30

4. Gastrointestinal colorectal cancer (Tomáš Šálek)

1. Gerard, JP. Randomized multicenter phase III trial comparing two neoadjuvant chemo-radiotherapy (CT-RT) regimens (RT45-Cap vs RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC). Results of the ACCORD 12/0405 PRODIGE 2.
2. Wolmark, N. A phase III trial comparing mFolfox6 to mFolfox 6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.
3. Tejpar, S. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5-FU-LV and irinotecan (PETAC 3 – EORTC 40993 – SAKK 60/00 trial).
4. Aschele, C. Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR (Studio Terapia Adiuvante Retto)-01 randomized phase III trial.

15.30 – 16.00

5. Gastrointestinal noncolorectal cancer (Mária Wágnerová)

1. Van Cutsem, E. Efficacy results from ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
2. Schuhmacher, C. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC Phase III Trial #40954.
3. James, R. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/FU in squamous cell carcinoma of the anus (ACT II).
4. Valle, J. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomized phase III trial (the UK ABC-02 trial).
5. Neoptolemos, J. ESPAC-3(v2) – A multicentre, international, open label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma.
6. Arnold, R. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.

16.00 – 16.30

9. Varia – head and neck, public health, survivorship (Juraj Beniak)

1. Hitt, R. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU (PF) or docetaxel/cisplatin/5-FU (TPF) followed by chemoradiotherapy (CRT) versus CRT alone as first line treatment of unresectable locally advanced head and neck cancer (LAHNC).
2. Gillison, M. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129.
3. Mueller, R. Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases – results of the EORTC 22952-26001 study.
4. Nathan, P. Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
5. Ryan, J. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.
6. Jean-Pierre P. Neuroprotective effects of SSRI among 781 cancer patients receiving chemotherapy: A URCC CCOP Study.

16.30 – 17.00

Discussion

17.00 – 17.15

Farewell

- **Termín / Date:**
3. október 2009/3rd October 2009
- **Miesto / Place:**
Holiday Inn, Bajkalská 25/A, Bratislava
- **Organizátor / Organizer:**
POKO Poprad, s. r. o., Slovenská onkologická spoločnosť Slovenskej lekárskej spoločnosti
- **Organizačný výbor / Organizing Committee:**
doc. MUDr. Igor Andrašina, CSc., VOÚ, Košice, Slovakia
prim. MUDr. Juraj Beniak, POKO Poprad, Slovakia
MUDr. Marián Kakalejčík, POKO Poprad, Slovakia
prof. MUDr. Ivan Koza, DrSc., NOÚ, Bratislava, Slovakia
doc. Jozef Mardiak, CSc. NOÚ, Bratislava, Slovakia
MUDr. Mária Rečková, POKO Poprad, Slovakia
prof. MUDr. Stanislav Špánik, CSc., OÚSA, Bratislava, Slovakia
- **Prednášajúci, predsedajúci / Faculty:**
doc. MUDr. Igor Andrašina, CSc., VOÚ, Košice, Slovakia
MUDr. Juraj Beniak, POKO Poprad, Slovakia
doc. MUDr. Peter Beržinec, CSc., OÚTaRCH, Nitra, Slovakia
Univ. Prof. Thomas Brodowicz, MD, Medical University, Vienna, Austria
Prof. Tanja Čufer, MD, PhD., University Clinic, Golnik, Slovenia
prim. MUDr. Pavol Dubinský, PhD, VOÚ, Košice, Slovakia
doc. MUDr. Jan Hudeček, CSc., KHT MFN, Martin, Slovakia
doc. MUDr. Peter Kasan, CSc., NÚTaRCH, Bratislava, Slovakia
prof. MUDr. Ivan Koza, DrSc., NOÚ, Bratislava, Slovakia
prim. MUDr. Vladimír Malec, PhD., FNŠP, Banská Bystrica, Slovakia
doc. MUDr. Jozef Mardiak, CSc., NOÚ, Bratislava, Slovakia
prim. MUDr. Tibor Packáň, VOÚ, Košice, Slovakia
prim. MUDr. Tomáš Šálek, NOÚ, Bratislava, Slovakia
prof. MUDr. Stanislav Špánik, CSc., OÚSA, Bratislava, Slovakia
Prof. Jan B. Vermorken, MD, PhD., Antwerp University Hospital, Belgium
MUDr. Andrej Vranovský, NOÚ, Bratislava, Slovakia
doc. MUDr. Mária Wágnerová, CSc., VOÚ, Košice, Slovakia
- **Mediálny partner / Media partner:**
SOLEN, s. r. o.
- **Oficiálny kongresový jazyk / official conference language:**
slovenčina, angličtina / *Slovak, English.*
- **Podujatie bude ohodnotené CME kreditmi. / The attendees will receive CME credits.**